CRESCENT BIOPHARMA INCCBIO
ASignal's systematic analysis rates CBIO as Bearish.
Reflects the latest available analysis · analyzed Sep 27, 2026
The case on CBIO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health with debt-to-equity ratio of 0.01x
- High cash position with $171.59M total cash and low debt
- High liquidity with current ratio of 9.66x and quick ratio of 9.26x
- Gross margin at 100.00% indicating strong pricing power or pure-play service model
- Price near lower Bollinger Band (13.52) suggesting potential reversal
- Negative MACD histogram and declining momentum
- Operating margin of -1432.63% signaling severe cost or operational issues
- Negative operating cash flow of -$72.68M
- High valuation metrics: EV/Revenue 36.41x, Price/Sales 43.73x despite no profitability
- No Reddit mentions, suggesting lack of retail investor interest or awareness
See the full verdict on CBIO
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CBIO
Most investors never get a second opinion, let alone several. ASignal runs CBIO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.